Rabolan

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rabolan

Rabolan is a synthetic, prescription-only pharmaceutical preparation used primarily as an Antihypertensive Agent to manage high blood pressure. Its identity is defined by its sole active component, Losartan (as the Losartan potassium salt), which is categorized as an Angiotensin II Receptor Blocker (ARB).

Quick Facts Description
Active Ingredient Losartan potassium
Form Oral tablet
Pharmacological Class Angiotensin II Receptor Blocker (ARB)
Common Purpose Antihypertensive Agent
Origin Synthetic, non-peptide compound

What Type of Medicine is Rabolan?

The medication belongs to the pharmacological class known as Angiotensin II Receptor Blockers (ARBs). This classification means the drug's mechanism involves interfering with the body's pressure-regulating system, making it an effective Antihypertensive Agent. The use of Losartan is characterized by its role in controlling elevated blood pressure.

Losartan is a non-peptide compound supplied as a single-ingredient product in an oral tablet form. This formulation, distinct from combination products, positions Rabolan for patients requiring targeted monotherapy for blood pressure control.


What is the General Purpose of Losartan?

The general purpose of Losartan is to act as an effective Antihypertensive Agent, which primarily helps stabilize and lower blood pressure to reduce chronic strain on the cardiovascular system.

The core physiological action is that the AT1 receptor antagonism prevents the powerful hormone Angiotensin II from signaling the blood vessels to constrict and tighten. By blocking this signal, Rabolan promotes vasodilation (vessel relaxation) and decreases overall peripheral resistance, allowing blood to flow more smoothly. This fundamental benefit is typically employed in a scenario where a patient requires sustained, daily control of high blood pressure to mitigate long-term cardiac and arterial damage.

Regulatory References

  1. Losartan: DailyMed (NIH/NLM)
  2. Losartan - StatPearls (NCBI Bookshelf)

What side effects are possible with Rabolan?

Official Adverse Reactions

The official safety profile of Rabolan (Losartan), an Angiotensin II Receptor Blocker, classifies adverse reactions based on their documented frequency in clinical use, which includes categories such as Common, Uncommon, and Rare, as defined in regulatory documents.

Classification Representative Adverse Reactions (System-Organ Class)
Common (1% to 10%) Dizziness, upper respiratory infection, nasal congestion, back pain, headache, fatigue, diarrhea, abdominal pain.
Uncommon (0.1% to < 1%) Palpitations, angina pectoris, symptomatic hypotension, vomiting, rash, vertigo.
Rare (< 0.1%) Angioedema (swelling of the face, throat, and tongue), hepatitis, syncope, cerebrovascular accident (CVA), rhabdomyolysis.

Serious Safety Constraints

Official regulatory labeling highlights several critical safety considerations:

  • Fetal Toxicity (Boxed Warning): Losartan can cause fetal harm or death when administered during the second and third trimesters of pregnancy. Use is contraindicated during this period.
  • Renal and Electrolyte Issues: Changes in renal function, including renal failure, have been reported in susceptible patients. The official documentation also notes a risk of hyperkalemia (high potassium) and mandates the close monitoring of serum potassium and creatinine concentrations during treatment.
  • Timing of Hypotension: Symptomatic low blood pressure is documented as being more likely to occur after the first dose or following a dose increase in patients who are volume-depleted.
  • Contraindications: Use is contraindicated in patients with diabetes mellitus who are concurrently taking aliskiren-containing products. Furthermore, the medicine is not recommended for use in individuals with severe hepatic impairment, as stated in regulatory texts.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation for Rabolan (Losartan) defines the overdosage profile strictly by an exaggerated extension of its therapeutic blood pressure-lowering effect.

Documented Overdose Manifestations

The primary documented presentation of an overdosage is severe arterial hypotension (extremely low blood pressure), which can lead to associated symptoms such as pronounced dizziness or fainting (syncope). Disturbances in heart rate are also listed as possible clinical signs, including both tachycardia (fast heart rate) and bradycardia (slow heart rate). For neonates and infants exposed in utero, the official labeling requires special consideration due to the documented risk of severe hypotension and oliguria (decreased urine output).

Emergency Actions and Clinical Management

When an overdosage is suspected, the mandated action is to seek immediate medical attention or contact Poison Control immediately. Urgent medical help must be sought if the individual exhibits severe symptoms such as collapse, seizure, or trouble breathing. Since no specific antidote is known for Losartan, the official clinical management strategy is defined as symptomatic and supportive treatment. This includes continuous close observation and monitoring of blood pressure and renal function. Regulatory documents confirm that Losartan and its active metabolite are not effectively removed by hemodialysis in overdose situations.

Therapeutic Uses of Rabolan

Quick Facts: Therapeutic Domains

  • Supports the management of high blood pressure (hypertension).
  • Appropriate for use in patients with high blood pressure and left ventricular hypertrophy (enlarged heart muscle) to help reduce the potential risk of stroke.
  • Used in the management of kidney disease (diabetic nephropathy) in individuals with type 2 diabetes and a history of hypertension.

Rabolan is a medication utilized in healthcare settings for the management of specific cardiovascular and renal conditions. Its primary use is in the treatment of high blood pressure, also known as hypertension, in adults and in certain pediatric patients (ages 6 and older). Maintaining blood pressure within a healthy range is part of a comprehensive strategy to help manage the risk of serious cardiovascular events, such as a heart attack or stroke.

In patients who have been identified with hypertension and left ventricular hypertrophy, Rabolan is also intended to reduce the potential for a stroke. Additionally, the medication supports the treatment regimen for diabetic nephropathy, a form of kidney disease, in adults who have type 2 diabetes and high blood pressure, where it may assist in moderating the progression of the condition.

Eligibility and Restrictions for Use

Rabolan (Losartan potassium) is subject to specific regulatory rules defining who may use the medicine and under what conditions. These rules are non-negotiable and are documented in official government prescribing information.

Populations for Whom Use is Contraindicated

Use is strictly prohibited in the following populations:

  • Women who are in the second or third trimesters of pregnancy.
  • Patients with documented hypersensitivity to Losartan or any component of the product.
  • Patients with severe hepatic impairment.
  • Patients with diabetes mellitus who are receiving aliskiren.

Age-Related and Conditional Eligibility

Population Group Regulatory Status
Adults (18+ years) Approved for general use in labeled indications.
Children/Adolescents (6 to 18 years) Approved for the treatment of hypertension.
Children Under 6 years Not recommended; safety and efficacy have not been established.
Nursing Mothers Not recommended (due to unknown excretion into human milk).

Eligibility is restricted in patients with mild-to-moderate hepatic impairment or those who are volume- or salt-depleted (e.g., from high-dose diuretics). Furthermore, use is not recommended in pediatric patients with a Glomerular Filtration Rate (GFR) less than 30 mL/min/1.73 m^2.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define specific interaction patterns for Rabolan (Losartan potassium) based on pharmacodynamic and pharmacokinetic mechanisms.

Contraindicated and Restricted Combinations

Co-administration with Aliskiren is formally contraindicated in patients with diabetes mellitus or specific renal impairment (GFR < 60 mL/min/1.73 m^2). The combination of Rabolan with ACE Inhibitors is also generally not recommended due to the risks associated with Dual Blockade of the Renin-Angiotensin System (RAS).

Pharmacodynamic Interactions

Co-administration with Agents Increasing Serum Potassium (such as potassium-sparing diuretics, potassium supplements, or heparin) poses an increased risk of hyperkalemia due to an additive effect. Combining Rabolan with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including COX-2 inhibitors, may officially lead to the attenuation of the blood pressure-lowering effect and heightened risk of worsening renal function, particularly in the elderly or those with compromised kidney function. Additionally, co-use with Lithium has been associated with reversible increases in serum lithium concentrations and documented toxicity.

Pharmacokinetic Changes

The medicine is metabolized to its active form primarily via CYP enzymes. Fluconazole, a CYP2C9 inhibitor, is officially documented to significantly increase the exposure (AUC) of Losartan while simultaneously reducing the active metabolite's exposure. Conversely, strong inducers like Phenobarbital and Rifampicin are noted to reduce the plasma exposure of Losartan and its active metabolite. In patients with hepatic impairment, the clearance of Losartan is slower, resulting in a significantly increased drug exposure.

Mechanism of Action

Enzyme-Mediated Proton Pump Inhibition

This domain covers the direct biochemical action of the drug: it irreversibly binds to the H^+/ K^+-ATPase enzyme (the proton pump) on the secretory surface of the gastric parietal cells. This binding is a key molecular modification that blocks the final step of acid secretion, which results in the sustained suppression of hydrogen ion efflux.


Regulation of Gastric Acid Secretory Cascade

This mechanistic cluster involves the physiological pathway where the drug modulates a key system: it acts as a prodrug that must be activated by the acidic environment within the parietal cell's canaliculi. The subsequent covalent bond formation with the proton pump causes a sustained physiological consequence and alters gastric luminal pH dynamics.


Rapid Biological System Engagement

This mechanism focuses on the drug's distinctive physical chemistry: Rabeprazole has a higher pKa value than other agents in its class. This feature leads to rapid activation of signaling suppression, facilitates a measurable adjustment in physiological response, and accelerates the modulation of hydrogen ion concentration within the gastric lumen.

Dosage and Administration Information

Rabolan (Losartan) is an Angiotensin II Receptor Blocker administered orally in the form of tablets or a prepared suspension. It is intended for once daily use and may be taken consistently with or without food.

Standard Administration

The usual starting dose for adults managing hypertension or diabetic nephropathy is 50 mg once daily. Following the initial 3 to 6 weeks of therapy—the time required to achieve the full treatment effect—the dose may be adjusted based on the individual's response, up to a maximum recommended dose of 100 mg once daily.

Population-Specific Use

A lower initial dose of 25 mg once daily is necessary for specific patient populations. This includes individuals diagnosed with mild-to-moderate hepatic impairment and those who are intravascularly volume-depleted (for example, due to high-dose diuretic therapy). For pediatric patients aged 6 years and older, the initial dosing is weight-based, starting at 0.7 mg/kg once daily.

Key Procedural Notes

If a dose is missed, the protocol indicates not to take a double dose to catch up, but instead to return to the regular schedule. Tablets are intended to be swallowed whole with water. Furthermore, the protocol requires that salt or volume depletion should be corrected before therapy initiation, or the mandatory use of the lower starting dose must be implemented.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Clinical Research

Clinical research has explored the drug’s potential activities relevant to inflammatory pathways. Studies have evaluated the drug's use in participants with the specified chronic condition, focusing on indicators such as inflammation markers and scores for participant-reported symptoms.


Combination and Monotherapy Studies

  • Combination Therapy: Research examined whether the combination therapy was associated with changes in measured outcomes and time to onset of observation. Findings were mixed; some studies reported statistical associations with changes in measured outcomes, while others did not detect a significant difference compared to control.
  • Monotherapy: Studies examined the drug administered alone, typically over a 6-week period. These trials often used various scales to quantify symptom severity. Data suggested that the proportion of participants reporting a reduction in scores varied significantly between studies.

Dosage and Key Outcome Measures

Studies often examined administration at the lowest dose level explored in the research. Different dosing schedules were evaluated in clinical trials to determine the impact on measured plasma concentration and adverse event reporting. Findings suggested that higher doses were associated with a greater frequency of reported side effects.

Clinical trials reported an evaluation of sleep quality measures and the frequency of symptom flare-ups over the study period. Initial reports suggested that the findings regarding observed changes in sleep quality measures were inconsistent across the research analyzed. Furthermore, studies measured changes in systemic inflammation markers such as C-reactive protein (CRP). Research is ongoing to determine the consistency and magnitude of the change in these biomarkers.


Special Populations and Safety Profile

  • Hepatic Impairment: Studies evaluated the administration of this medication in participants with liver impairment, and findings suggested careful consideration is necessary. Researchers observed that metabolism may be altered in this population, which could affect drug concentration.
  • Geriatric Patients: Research examined the tolerability and effect profile in participants aged 65 and over. Reports indicated that the incidence of adverse events was similar between the geriatric and younger adult participants studied, though data remains limited for those over 75.

Research evaluated the concentration and duration of the pharmacological effect following administration. Data indicated that the frequency of reported adverse events varied across the different populations examined in the research.

Frequently Asked Questions (FAQ)

Common questions about Rabolan (FAQ)

Q: Is Rabolan a medication that needs to be taken for a short period, or is it typically long-term?

For managing chronic conditions such as high blood pressure, official regulatory documents state that Rabolan is typically intended for long-term use. It helps control the condition but is not a cure. Consult your prescribing doctor regarding the appropriate duration of treatment.

Q: Is it normal to feel a bit dizzy or lightheaded when first starting Rabolan?

Yes, regulatory documents indicate that dizziness or lightheadedness is a common side effect of Rabolan. This is documented as being more likely when starting the medication or following a dose increase. Patients are generally advised to be cautious when changing position, especially when starting treatment.

Q: Does Rabolan cause a persistent dry cough, similar to some other blood pressure medications?

Official information indicates that Rabolan (Losartan) is less likely to cause a persistent dry cough compared to medications in the ACE inhibitor class. While cough is listed as an adverse reaction in some product information, it is not listed as a frequent side effect in the official product information.

Q: Are there any signs of a serious reaction to Rabolan that I should be aware of immediately?

Yes, signs of a serious allergic reaction, known as angioedema, require immediate attention. These symptoms include swelling of the face, lips, tongue, and throat, which may cause difficulty breathing. If you experience any of these signs, prompt emergency medical attention is advised.

Q: Can Rabolan potentially cause changes in my potassium levels, and if so, what are the symptoms?

Losartan can cause an increase in potassium levels, known as hyperkalemia. The official safety information emphasizes the importance of closely monitoring serum potassium levels during treatment. Symptoms of high potassium can include an irregular heartbeat, muscle weakness, or a slow heart rate.

Q: Is there a known interaction between Rabolan and alcohol consumption?

According to official drug interaction information, taking Rabolan with alcohol may have an additive effect in lowering blood pressure. This can increase the risk of symptoms such as dizziness, lightheadedness, and fainting.

Q: Does taking Rabolan affect my ability to drive or operate machinery?

Due to the possibility of experiencing dizziness or drowsiness while on Rabolan, patients are advised to use caution when driving or operating machinery until they know how the medication affects them.

Q: Why might a doctor prescribe Rabolan for high blood pressure and an enlarged heart (left ventricular hypertrophy)?

Official indications state that Rabolan is prescribed to reduce the risk of stroke in patients who have high blood pressure and a specific type of heart enlargement called Left Ventricular Hypertrophy (LVH). This is a defined therapeutic use based on clinical research.

Q: Does Rabolan help with other heart conditions like heart failure, beyond high blood pressure?

While Rabolan is primarily indicated for high blood pressure, the official label includes precautions for its use in patients with severe congestive heart failure. Any use of Rabolan in the context of heart failure management would be at the discretion of a healthcare professional as part of a specialized treatment plan.

Q: What is the connection between Rabolan and uric acid levels or gout?

Regulatory documents note that Losartan has uricosuric properties, meaning it can help lower the level of uric acid in the blood by increasing its excretion in the urine. This effect is relevant for patients with high blood pressure who also have high uric acid or gout.

Q: Can taking Rabolan affect a person's sex drive or cause erectile dysfunction?

Sexual dysfunction is generally not listed as a common or frequent adverse reaction in the official documentation. For specific concerns, consulting the full list of official adverse events is recommended.

Q: What is the significance of the active metabolite (EXP3174) of Rabolan?

Rabalan (Losartan) is known as a prodrug, meaning it converts into an active metabolite in the body, which is called EXP3174. This metabolite is actually responsible for most of the drug’s intended action—blocking the angiotensin II receptor—and contributes significantly to its blood pressure-lowering effect.

Q: Do any side effects of Rabolan typically go away after my body adjusts to the medication?

Based on patient information from official sources, some common side effects, such as mild dizziness or minor digestive discomfort, may lessen or go away over time as your body adjusts to the medication. Continuing the prescribed regimen is generally recommended unless a healthcare provider instructs otherwise.

Q: Are there long-term side effects associated with taking Rabolan for many years?

The medication is intended for long-term management of high blood pressure. While all known side effects are reported regardless of duration of use, official guidelines recommend the regular monitoring of kidney function and potassium levels throughout long-term therapy.

Q: How is Rabolan excreted from the body (urine, feces)?

Official clinical pharmacology information confirms that Losartan and its active metabolite are cleared from the body through two main routes: elimination in the urine and elimination in the feces (via bile).

Q: Can Rabolan cause insomnia or sleep disturbances?

Sleep disturbances or insomnia are not typically listed as a common or frequent adverse reaction in the official regulatory documentation. Any changes in sleep patterns should be discussed with a healthcare provider.

How should Rabolan be stored and disposed of?

Rabolan (Losartan potassium) must be stored and handled according to the following official requirements to maintain its stability and effectiveness.


Storage Conditions

Product Form Temperature Requirement Stability Constraint
Tablets Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F). Protect from moisture.
Prepared Suspension Must be refrigerated at 2 C to 8 C (36 F to 46 F). Stable for four weeks; must not be frozen.

The medicine must be stored out of the reach of children to prevent accidental ingestion.


Disposal Instructions

Unused or expired Rabolan tablets or suspension must be disposed of strictly according to local regulations. Follow established pharmaceutical waste protocols in your area for safe discarding.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Rabolan found in:

A-Z Index: